Search
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Invitrogen
Rosiglitazone Recombinant Mouse Monoclonal Antibody (4G6)
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
图: 1 / 1
Rosiglitazone Antibody (MA566331) in SDS-PAGE
SDS-PAGE characterization of Rosiglitazone under reducing conditions. Lane M: Protein marker (kDa); Lane RGT: Purified Rosiglitazone Recombinant Monoclonal (Product # MA566331). Rosiglitazone showing heavy chain (~50 kDa) and light chain (~25 kDa). Gels were stained with Coomassie Brilliant Blue R-633.
产品信息
MA566331
产品规格
种属反应
Chemical
宿主/亚型
Mouse
/ IgG
Expression System
CHO cells
分类
Recombinant Monoclonal
类型
Antibody
克隆号
4G6
抗原
Conjugate of RGT hapten and KLH.
偶联物
形式
Liquid
浓度
4.4 mg/mL
纯化类型
Protein G
保存液
PBS
内含物
0.09% sodium azide
保存条件
-20°C
运输条件
Ambient (domestic); Wet ice (international)
靶标信息
Rosiglitazone is a thiazolidinedione class drug used for the treatment of type 2 diabetes mellitus. It functions as a high-affinity agonist of the nuclear receptor peroxisome-proliferator-activated receptor-gamma (PPARgamma), which plays a crucial role in regulating glucose and lipid metabolism, thereby improving insulin sensitivity. The gene location for PPARgamma is on chromosome 3p25.2, and its structure includes a ligand-binding domain that facilitates the binding of rosiglitazone, leading to the modulation of gene expression involved in glucose homeostasis. Despite its efficacy, rosiglitazone has been associated with adverse cardiovascular effects, prompting the synthesis of derivatives such as rosiglitazone-ferulic acid-nitric oxide donor trihybrids to mitigate these side effects. Bioequivalence studies have shown that different formulations of rosiglitazone, such as hydrochloride and maleate, are comparable in terms of absorption and tolerance.
仅用于科研。不用于诊断过程。未经明确授权不得转售。
篇参考文献 (0)
您是否在文献中引用过该产品？请点击下方按钮邮件告知我们。
